MicroRNA-155 is a predictive marker for survival in patients with clear cell renal cell carcinoma

International Journal of Urology

Volumn 20, Issue 5, 2013, Pages 468-477

  Shinmei, Shunsuke ^a   Sakamoto, Naoya ^a   Goto, Keisuke ^a   Sentani, Kazuhiro ^a   Anami, Katsuhiro ^a   Hayashi, Tetsutaro ^a   Teishima, Jun ^a   Matsubara, Akio ^a   Oue, Naohide ^a   Kitadai, Yasuhiko ^a   Yasui, Wataru ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Hypoxia inducible factor 1 ; Micro ribonucleic acid; Micro ribonucleic acid 155; Quantitative reverse transcript polymerase chain reaction; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA; MICRORNA 137; MICRORNA 155; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY; KIDNEY NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84877621093     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.03182.x     Document Type: Article

References (30)

1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009; 373: 1119-1132.
2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N. Engl. J. Med. 1996; 335: 865-875.
3. Chow TF, Mankaruos M, Scorilas A etal. The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. J. Urol. 2010; 183: 743-751.
4. White NM, Bui A, Mejia-Guerrero S etal. Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs. Biol. Chem. 2010; 391: 411-423.
5. Yousef GM. microRNAs: a new frontier in kallikrein research. Biol. Chem. 2008; 389: 689-694.
6. Lu J, Getz G, Miska EA etal. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
7. White NM, Bao TT, Grigull J etal. miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J. Urol. 2011; 186: 1077-1083.
8. Neal CS, Michael MZ, Rawlings LH, Van der Hoek MB, Gleadle JM. The VHL-dependent regulation of microRNAs in renal cancer. BMC Med. 2010; 8: 1.
9. Petillo D, Kort EJ, Anema J, Furge KA, Yang XJ, Teh BT. MicroRNA profiling of human kidney cancer subtypes. Int. J. Oncol. 2009; 35: 109-114.
10. Juan D, Alexe G, Antes T etal. Identification of a microRNA panel for clear cell kidney cancer. Urology 2010; 75: 835-841.
11. Nakada C, Matsuura K, Tsukamoto Y etal. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J. Pathol. 2008; 216: 418-427.
12. Jung M, Mollenkopf HJ, Grimm C etal. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J. Cell. Mol. Med. 2009; 13: 3918-3928.
13. Gottardo F, Liu CG, Ferracin M etal. Micro-RNA profiling in kidney and bladder cancers. Urol. Oncol. 2007; 25: 387-392.
14. Yi Z, Fu Y, Zhao S, Zhang X, Ma C. Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues. J. Cancer Res. Clin. Oncol. 2010; 136: 855-862.
15. Chow TF, Youssef YM, Lianidou E etal. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin. Biochem. 2010; 43: 150-158.
16. Slaby O, Jancovicova J, Lakomy R etal. Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J. Exp. Clin. Cancer Res. 2010; 29: 90.
17. Jiang S, Zhang HW, Lu MH etal. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010; 70: 3119-3127.
18. Yanaihara N, Caplen N, Bowman E etal. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189-198.
19. Greither T, Grochola L, Udelnow A, Lautenschläger C, Würl P, Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int. J. Cancer 2010; 126: 73-80.
20. Han ZB, Chen HY, Fan JW, Wu JY, Tang HM, Peng ZH. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J. Cancer Res. Clin. Oncol. 2012; 138: 153-161.
21. Shibuya H, Iinuma H, Shimada R, Horiuchi A, Watanabe T. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology 2010; 79: 313-320.
22. Wotschofsky Z, Meyer HA, Jung M etal. Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. Anal. Biochem. 2011; 417: 233-241.
23. O'Connell RM, Chaudhuri AA, Rao DS, Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc. Natl. Acad. Sci. U.S.A. 2009; 106: 7113-7118.
24. Gironella M, Seux M, Xie MJ etal. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc. Natl. Acad. Sci. U.S.A. 2007; 104: 16170-16175.
25. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002; 2: 38-47.
26. Bos R, van Diest PJ, de Jong JS, van der Groep P, van der Valk P, van der Wall E. Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 2005; 46: 31-36.
27. Bruning U, Cerone L, Neufeld Z etal. MicroRNA-155 promotes resolution of hypoxia-inducible factor-1α activity during prolonged hypoxia. Mol. Cell. Biol. 2011; 31: 4087-4096.
28. Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Bergh A, Ljungberg B. Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray. Eur. Urol. 2006; 50: 1272-1277.
29. Moon EJ, Brizel DM, Chi JT, Dewhirst MW. The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antioxid. Redox Signal. 2007; 9: 1237-1294.
30. Schultz L, Chaux A, Albadine R etal. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell carcinomas. Am. J. Surg. Pathol. 2011; 35: 1549-1556.